pharmaceuticals AM market analysis — 2026-09-15

The tariff regime reshaping U.S. drug manufacturing is producing headline commitments rather than confirmed capacity. Large manufacturers have pledged hundreds of billions of dollars toward domestic plants for biologics and injectables under a tiered tariff structure that rewards U.S. investment and largely spares generics. Analysts at IntuitionLabs caution that payback periods stretching close to a decade, alongside lengthy regulatory approval timelines, mean the incentives alone may not be enough to justify relocating production quickly. China’s dominant share of active pharmaceutical ingredient supply remains a structural vulnerability, even as current carve-outs continue to shield Chinese-made generics and APIs from the steepest duties.

On the innovation side, FDA new-drug approvals eased modestly in 2025, a shift researchers link to political and administrative factors rather than any underlying slowdown in scientific output. Oncology, led by non-small cell lung cancer indications, continued to draw the most regulatory activity, alongside a wave of peptide and oligonucleotide therapies. Gene-therapy approvals reaching the market in 2026, including an AAV-vector treatment for a rare metabolic disorder, indicate that advanced-modality pipelines are progressing separately from the trade-policy disruption. Together, the supply-chain restructuring and the approval trend point in different directions, leaving the sector’s near-term picture mixed.